γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
News|Articles|January 1, 2002
Tenofovir: The first nucleotide reverse transcriptase inhibitor for treatment of patients with HIV-1 infection
Tenofovir disoproxil fumarate (Viread) recently gained accelerated FDA approval. It is the first member of a new antiretroviral class and also the first antiretroviral approved on the basis of efficacy trials conducted almost exclusively in treatment-experienced patients. This Focus article reviews these studies and considers how other pending and planned trials may refine tenofovir's role.
Advertisement
Advertisement
Related to this article
Upstream payment accuracy should reduce avoidable noise before it reaches those downstream functions.
The results come several months after the FDA approved Lisraya for dermatomyositis.
Psychedelic therapies are nearing FDA decisions, but people with HIV, many covered by Medicaid, have been left out of nearly all trials, commentary authors argue.
Christopher Stanley, M.D., MBA, says Henry Ford Health now projects its 2027 employee healthcare insurance premiums to increase half as much as what had been expected, partly because of Populance’s to bring about cost-effective care.
Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Calibrating biologic treatment of HS to the response patterns to biologics
2
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
3
Quick Q&A: Christopher Stanley, M.D., MBA, on population health and healthcare affordability
4
Patience and persistence define one Yale gastroenterologist’s approach to MASLD
5